#ASCO 2017 ANDROGEN RECEPTOR PREDICT THERAPY ANTI-ESTROGEN BREAST CANCER
Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2− Breast Cancer: KEYNOTE-756
Comentários
Postar um comentário